...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Iranian Journal of Neurology >Safety assessment of anticoagulation therapy in patients with hemorrhagic cerebral venous thrombosis
【24h】

Safety assessment of anticoagulation therapy in patients with hemorrhagic cerebral venous thrombosis

机译：出血性脑静脉血栓形成患者抗凝治疗的安全性评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundAnticoagulation therapy is a routine treatment in patients with hemorrhagic cerebral venous thrombosis (CVT). However, fear of hemorrhagic complications and deterioration course following anticoagulation often disturbs the responsible physician.MethodsThis was a Prospective observational study on consecutive CVT patients with hemorrhagic venous infarction or subarachnoid hemorrhage (SAH) admitted in Ghaem Hospital, Mashhad, Iran, during 2006-2012. The diagnosis of CVT in suspected cases was confirmed by magnetic resonance imaging/magnetic resonance venography (MRI/MRV), and computerized tomography (CT) angiography following established diagnostic criteria. Demographic data, clinical manifestations from onset to end of the observation period, location of thrombus, location and size of infarction and hemorrhage, and clinical course during treatment were recorded. Choice of the treatment was left to the opinion of the treating physician. Clinical course during 1 week of treatment was assessed based on the baseline modified National Institute of Health Stroke Scale (NIHSS) score. Three or more points decrease or increase of modified NIHSS after 1 week of treatment was considered as improvement or deterioration courses, respectively. Other clinical courses were categorized as stabilization course.Results102 hemorrhagic CVT patients (80 females, 22 males) with mean age of 38.6 ± 8 years were prospectively investigated. Of the 102 hemorrhagic CVT patients in the acute phase, 52 patients (50.9%) were anticoagulated with adjusted dose intravenous heparin infusion and 50 cases (49.1%) received subcutaneous enoxaparin 1mg/Kg twice daily. Decreased consciousness had a significant effect on the clinical course of the patients (X2 = 9.493, df = 2, P = 0.009). Presence of SAH had no significant effect on the clinical course of our anticoagulated hemorrhagic CVT cases (X2 = 0.304, df = 2, P = 0.914). Extension of Infarction in more than two thirds of a hemisphere had a significant influence on the distribution of clinical courses (X2 = 5.867, df = 2, P = 0.044). Difference in distribution of clinical course among the two groups of our hemorrhagic CVT patients was not significant (X2 = 8.14, df = 1, P = 0.87).ConclusionPatients with hemorrhagic CVT without other contraindication for anticoagulation should be treated either with dose-adjusted intravenous heparin or body-weight-adjusted subcutaneous low molecular-weight heparin.
机译：背景技术抗凝治疗是出血性脑静脉血栓形成（CVT）患者的常规治疗方法。然而，担心抗凝后的出血并发症和恶化过程通常会打扰负责的医生。 。可疑病例中的CVT诊断已通过磁共振成像/磁共振静脉造影（MRI / MRV）并按照既定的诊断标准进行了计算机断层扫描（CT）血管造影。记录人口统计数据，从发病到观察期结束的临床表现，血栓的位置，梗塞和出血的位置和大小以及治疗期间的临床过程。治疗的选择留给主治医师。根据基线改良的美国国立卫生研究院卒中量表（NIHSS）评分评估治疗1周期间的临床病程。治疗1周后修饰的NIHSS降低或增加三点或更多点分别被视为改善或恶化过程。结果前瞻性调查了102例CVT出血患者（女性80例，男性22例），平均年龄38.6±8岁。在102例急性期出血性CVT患者中，有52例（50.9％）通过调整剂量的静脉肝素输注进行了抗凝治疗，而50例（49.1％）的患者每天两次皮下注射依诺肝素1mg / Kg。意识下降对患者的临床病程有重要影响（X2 = 9.493，df = 2，P = 0.009）。 SAH的存在对我们的抗凝性出血性CVT患者的临床病程没有显着影响（X2 = 0.304，df = 2，P = 0.914）。梗塞在半球的三分之二以上扩展对临床病程的分布有显着影响（X2 = 5.867，df = 2，P = 0.044）。两组出血性CVT患者的临床病程分布无显着差异（X2 = 8.14，df = 1，P = 0.87）。结论出血性CVT无其他抗凝禁忌症的患者应采用剂量调整的静脉注射治疗肝素或体重调整的皮下低分子量肝素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号